Patents by Inventor Lewis W. Dittert

Lewis W. Dittert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6608073
    Abstract: This invention provides a method of rapidly and reliably delivering codeine, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route to produce rapid onset of beneficial effects in the treatment of pain or cough. The present invention further provides pharmaceutical compositions comprising codeine, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms, with and without other analgesic and/or antitussive compounds.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: August 19, 2003
    Assignee: New Millennium Pharmaceutical Research, Inc.
    Inventors: Anwar A. Hussain, Lewis W. Dittert, Abeer M. Al-Ghananeem
  • Patent number: 6380175
    Abstract: The present invention is directed to a method for enhancing the delivery of delta-9-tetrahydrocannabinol (“THC”) to the brain of a mammal in need of treatment with this drug, by administering water-soluble prodrugs of THC intranasally.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: April 30, 2002
    Assignee: New Millennium Pharmaceutical Research, Inc.
    Inventors: Anwar A. Hussain, Lewis W. Dittert, Ali M. Qaisi, Ashraf Traboulsi
  • Patent number: 6369058
    Abstract: This invention provides a method of rapidly and reliably delivering folic acid, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route to produce rapid onset of beneficial effects in the treatment or prevention of Alzheimer's Disease and stroke. The present invention further provides intranasal pharmaceutical compositions comprising folic acid, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms, with and without other anti-Alzheimer's or anti-stroke compounds.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: April 9, 2002
    Assignee: New Millennium Pharmaceutical Research Inc.
    Inventors: Anwar A. Hussain, Lewis W. Dittert, Ashraf Traboulsi
  • Patent number: 6200591
    Abstract: This invention provides a method of rapidly and reliably delivering sildenafil, or derivatives thereof, alone or in combination with other compounds, to the systemic circulation by administration via the nasal route so as to produce virtually instantaneous onset of beneficial effects in the treatment of erectile dysfunction. The present invention further provides pharmaceutical compositions comprising sildenafil, or derivatives thereof, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms, with and without apomorphine.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: March 13, 2001
    Inventors: Anwar A. Hussain, Lewis W. Dittert
  • Patent number: 5985239
    Abstract: The present invention relates to N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters, and their use as agents for water disinfection and as mild oxidizing agents for the radiolabeling of oxidation-sensitive biomolecules.
    Type: Grant
    Filed: January 14, 1998
    Date of Patent: November 16, 1999
    Assignee: University of Kentucky Research Foundation
    Inventors: Anwar A. Hussain, Bassam Tashtoush, Lewis W. Dittert
  • Patent number: 5753701
    Abstract: The present invention relates to N-chloro-N-methyl glucamine and N-chloro-N-methyl glucamine esters, and their use as agents for water disinfection and as mild oxidizing agents for the radiolabeling of oxidation-sensitive biomolecules.
    Type: Grant
    Filed: October 25, 1996
    Date of Patent: May 19, 1998
    Assignee: University of Kentucky
    Inventors: Anwar A. Hussain, Bassam Tashtoush, Lewis W. Dittert
  • Patent number: 5424402
    Abstract: A kit and method of non-destructively radiolabelling a biomolecule substrate by halogenation, including the steps of: a) reacting a secondary amine with a chlorinating agent to produce an N-chloro secondary amine, (b) reacting the N-chloro secondary amine with a salt of a radiolabelled halogen to produce a radiolabelled halogenating agent, (c) reacting a solution of the biomolecule substrate with the radiolabelled halogenating agent, and (d) recovering a radiohalogenated biomolecule from the reaction of step (c). The kit and method allow for more complete iodination with a lessening of side reactions such as decomposition of the biomolecule substrate to be labelled.
    Type: Grant
    Filed: October 18, 1993
    Date of Patent: June 13, 1995
    Assignee: Board of Trustees of The University of Kentucky
    Inventors: Anwar A. Hussain, Lewis W. Dittert
  • Patent number: 5000869
    Abstract: A fabric-safe bleaching and cleaning detergent composition comprising a bleach stable surfactant and a polymer coated halogenated glycoluril compound having the formula ##STR1## wherein each R is independently selected from hydrogen, C.sub.1 -C.sub.10 straight or branched chain alkyl, aryl or alkyl substituted aryl; each X is independently selected from hydrogen, fluorine, chlorine, bromine and iodine and at least one X is not hydrogen and n is 0 or 1. 1,3,4,6-tetrachloroglycoluril is the preferred bleaching agent. The polymer coating is capable of hydrating and dissolving at a pH of greater than 6.0, preferably 7.2 to 11.0, and more preferably 9.5 to 11.0. Polymeric pharmaceutical enteric coating materials are particularly suitable as a coating material for the present invention.
    Type: Grant
    Filed: February 14, 1990
    Date of Patent: March 19, 1991
    Assignee: Safe Aid Products, Inc.
    Inventor: Lewis W. Dittert
  • Patent number: 4885287
    Abstract: The invention relates to a novel method of administering aspirin to achieve improved delivery thereof. The invention further relates to novel dosage forms of neutralized aspirin adapted for nasal administration, such as solutions, suspensions, gels and ointments. These dosage forms find utility in the treatment of conditions known to respond to the administration of aspirin, particularly in the treatment of migraine and in the mitigation of cardiovascular damage resulting from heart attack.
    Type: Grant
    Filed: August 9, 1988
    Date of Patent: December 5, 1989
    Assignee: University of Kentucky Research Foundation
    Inventors: Anwar A. Hussain, Lewis W. Dittert, Thomas S. Foster